SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following the finalization of its $250 million acquisition of Ask Sage, a key generative AI platform for secure defense and government applications. This strategic move is driving significant bullish sentiment among investors who anticipate new government and TSA contracts, reinforcing its position in the AI defense sector. However, ongoing discussions and repeatedly postponed votes concerning increased authorized shares are causing investor debate, contributing to the stock's notable volatility.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending due to its exceptionally low public float, positioning it as a prime candidate for a short squeeze. The community is actively discussing the company's significant cash reserves relative to its market valuation, fueling speculation about potential strategic alternatives like a merger. Many believe this combination of factors points to substantial untapped value and potential for rapid upward movement, drawing comparisons to other recent parabolic movers.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is actively trending as investors anticipate a potential housing market rebound in early 2026, driven by lower interest rates and the "January effect" for small-cap tech. Community sentiment is divided, with bulls optimistic about the company's strategic shift towards AI-powered real estate and its battle-tested leadership, while skeptics question past performance and the long-term profitability of its business model.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following its announcement of record December and Q4 2025 vehicle deliveries, surpassing key competitors. The community is buzzing with speculation about whether these strong delivery figures will finally translate into profitability in Q4 or 2026, and if the stock price will reflect the improving fundamentals amid ongoing frustration over perceived market manipulation. Many highlight the expanding battery swap network and multi-brand strategy as crucial long-term growth drivers.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to extreme recent volatility, including a significant price drop from earlier highs, which is happening alongside news of its blockchain technology expanding into luxury and fashion traceability. Community sentiment is sharply divided, with proponents highlighting its disruptive tech and potential for a short squeeze amidst a low float and high cost to borrow, while skeptics point to a history of reverse splits and ongoing dilution concerns.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending due to intense community debate surrounding an upcoming shareholder meeting, where a significant increase in authorized shares is a key proposal, fueling investor concerns over potential dilution and perceived management self-interest given the stock's underperformance against Ethereum. While some investors view recent declines as a buying opportunity, anticipating future staking revenue and a broader market rebound, many others express strong bearish sentiment, criticizing leadership actions and questioning the company's financial strategy.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending after announcing a strategic manufacturing partnership and a private placement that is expected to strengthen its balance sheet and scale production. This has ignited intense community discussion, with many anticipating a short squeeze fueled by its low public float, while others express caution regarding potential dilution from the private placement.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending as the community highlights its recent contract wins, including a significant European commercial space deal, and its diversified role across space infrastructure and defense systems. Many investors are actively discussing short squeeze potential and perceive the company as significantly undervalued, anticipating substantial long-term growth within the burgeoning space sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors eagerly await its Q4 delivery numbers, a key data point expected to drive significant price action. Bulls are anticipating strong growth from the energy division and future robotaxi deployments, while bears point to slowing EV sales, unfulfilled autonomy promises, and an elevated valuation, fueling a heated debate over the stock's direction.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending with intense community focus on an anticipated "Clarity Act" and potential supply shock, alongside recent developments like XRP ETF inflows and expanded institutional partnerships. While many foresee substantial price surges driven by these catalysts, there's also ongoing debate and frustration regarding its past price stagnation and the implications of Ripple's scheduled escrow releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html">announced</a> its intent to wind down operations and explore asset sales.iTeos said it decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value.The Board of Directors now intends to focus on leveraging the company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the company’s intellectual property and assets.iTeos ended the first quarter of 2025 with cash and investments of $624.3 million. Last month, the firm had said that it expects its cash balance to provide a runway through 2027.However, earlier this month, iTeos decided to <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">terminate</a> its collaboration with British pharmaceutical major GSK Plc for the development of experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy, and the companies subsequently decided to terminate the program and end the collaboration.iTeos CEO Michel Detheux had said the company is “truly disappointed” by the trial results and is taking “immediate steps” to preserve capital. &nbsp;On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_11_05_44_AM_png_7ce0e324ab.webp" alt="ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="67"><figcaption>ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user expressed optimism about the company’s decision to halt operations.<stembedurl>https://stocktwits.com/BullDriven/message/616043049</stembedurl><a href="https://stocktwits.com/symbol/ITOS">ITOS stock </a>is up approximately 29% this year but down by more than 40% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-gets-rmat-designation-for-prostate-cancer-therapy/ch0om35Rbs0">Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 

Equity

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Shares of iTeos Therapeutics, Inc. (ITOS) rocketed 20% on Tuesday morning after the company announced it has decided to terminate its collaboration with British pharmaceutical major GSK Plc for the development of its experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy. Hence, the two companies have decided to end the collaboration and terminate the program.iTeos <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-reports-topline-interim-results-galaxies-lung-201-study">also</a> ended new enrollment for a phase 3 trial of the combination.GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for the appropriate management of currently enrolled patients, iTeos said.iTeos CEO Michel Detheux said the company is “truly disappointed” by the trial results. The firm is taking “immediate steps” to preserve capital and maximise shareholder value and has engaged TD Cowen to advise on the process.“...given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets,” Detheux said, while adding that the company has a strong balance sheet to enable it to pursue opportunities.On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_9_51_08_AM_png_54cf65be0f.webp" alt="ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ITOS">ITOS stock</a> is up by about 5% this year but has declined by about 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/vehicle-prices-rose-in-april-after-trump-tariffs/chi8mIbRbZg">Cadillac, Tesla, GMC Vehicles Get More Expensive In April After Trump Tariffs, Shows Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

ITOS
ITeos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ITOS News

ITOSITeos Therapeutics Inc